Tirzepatide
Dual GIP / GLP-1 receptor agonist with strong Phase 3 evidence in type 2 diabetes (SURPASS) and obesity (SURMOUNT).
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
What the research shows
SURMOUNT-1 (n=2,539) showed up to ~22.5% body-weight reduction at 72 weeks at the 15 mg dose. SURPASS trials demonstrated robust HbA1c improvement vs comparators in type 2 diabetes.
What's still experimental
Direct head-to-head with semaglutide for cardiovascular outcomes is still maturing. Long-term durability of weight loss after discontinuation remains under study.
Anecdotal / community reports
Rapid weight-loss anecdotes are common; many ignore baseline lifestyle changes and gradual dose escalation that the trials used.
Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.
Live research
Updated hourly · sourced from PubMed + ClinicalTrials.govClinical trials (ClinicalTrials.gov)
- GLP1 Fasting Status and Gastric Retention Using Gastric UltrasoundRECRUITINGNCT07251803 · N/A · n=150 · 2026-02-03
- The Long COVID Treatment TrialACTIVE NOT RECRUITINGNCT07128082 · PHASE2 · n=1000 · 2025-10-30
- ECHO for Diabetes and Multiple Chronic Conditions StudyENROLLING BY INVITATIONNCT06451458 · NA · n=20 · 2024-10-16
- Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With ObesityRECRUITINGNCT07293325 · NA · n=66 · 2025-06-02
- The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 DiabetesCOMPLETEDNCT05078255 · NA · n=61 · 2022-01-27
Known risks
Similar profile to GLP-1 agonists. Prescription-only.
Reported side effects
GI side effects, injection-site reactions.
What requires medical supervision
Prescription medication with the same MTC/MEN-2 contraindications and similar GI/gallbladder safety considerations as GLP-1 monoagonists.
Questions for your clinician
- Is tirzepatide more appropriate than semaglutide for me, and why?
- What injection-site rotation and titration plan do you recommend?
- What labs should we follow?
Editorially curated references
Discussions about Tirzepatide
- 35Fat Loss·5/7/2026· 0SURMOUNT-1: tirzepatide weight-loss data summarized
SURMOUNT-1 (NEJM 2022, ~2,500 participants without diabetes) reported up to ~22.5% body-weight reduction at 72 weeks on the 15mg dose vs ~2.4% placebo. Dual GIP/GLP-1 agonism appears to outperform GLP-1-only on weight outcomes. Open questions: muscle mass preservation, long-term cardiovascular endpoints.
- 31Research Studies·5/7/2026· 0Questions to bring to your doctor before starting a GLP-1
If you're considering semaglutide or tirzepatide, here are evidence-based questions worth asking: (1) baseline labs you'd recommend? (2) what's our titration plan? (3) when do we re-evaluate? (4) plan if I stop — managed taper vs cold turkey? (5) interactions with my current meds?
- 27Side Effects·5/7/2026· 0Tirzepatide and muscle loss — what the evidence says
A common worry on GLP-1/GIP agonists is lean mass loss along with fat. SURMOUNT body-comp sub-analyses suggest the proportion of lean mass loss is roughly similar to lifestyle-only weight loss, but absolute lean loss can be larger because total loss is bigger. Resistance training + adequate protein (1.6-2.2g/kg) appears protective.